BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32842533)

  • 21. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2.
    Shang C; Lu YM; Meng LR
    Med Sci Monit; 2012 Apr; 18(4):BR149-55. PubMed ID: 22460089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
    Yoneyama K; Ishibashi O; Kawase R; Kurose K; Takeshita T
    Anticancer Res; 2015 Mar; 35(3):1401-10. PubMed ID: 25750291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.
    Li Q; Zhang C; Chen R; Xiong H; Qiu F; Liu S; Zhang M; Wang F; Wang Y; Zhou X; Xiao G; Wang X; Jiang Q
    Cancer Lett; 2016 Dec; 383(1):28-40. PubMed ID: 27693631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
    Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
    Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
    PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.
    Hiroki E; Akahira J; Suzuki F; Nagase S; Ito K; Suzuki T; Sasano H; Yaegashi N
    Cancer Sci; 2010 Jan; 101(1):241-9. PubMed ID: 19891660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters.
    Hakim SA; Raboh NM
    Int J Clin Exp Pathol; 2015; 8(10):13225-32. PubMed ID: 26722522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.
    Dong P; Konno Y; Watari H; Hosaka M; Noguchi M; Sakuragi N
    J Transl Med; 2014 Aug; 12():231. PubMed ID: 25141911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR).
    Wu D; Huang HJ; He CN; Wang KY
    Int J Gynecol Cancer; 2013 Sep; 23(7):1191-7. PubMed ID: 23851675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.
    Bignotti E; Ravaggi A; Romani C; Falchetti M; Lonardi S; Facchetti F; Pecorelli S; Varughese J; Cocco E; Bellone S; Schwartz PE; Rutherford TJ; Santin AD
    Int J Gynecol Cancer; 2011 Dec; 21(9):1613-21. PubMed ID: 21892093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
    Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
    Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome.
    Wadee R; Grayson W
    Ann Diagn Pathol; 2019 Apr; 39():92-104. PubMed ID: 30798077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium.
    Cao QJ; Belbin T; Socci N; Balan R; Prystowsky MB; Childs G; Jones JG
    Int J Gynecol Pathol; 2004 Oct; 23(4):321-9. PubMed ID: 15381901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Thyroid Receptor Interacting Protein 6 by MicroRNA-589-5p Inhibits Cell Proliferation, Migration, and Invasion in Endometrial Carcinoma.
    Wang Y; Dong L; Liu Y
    Cancer Biother Radiopharm; 2019 Oct; 34(8):529-536. PubMed ID: 31424277
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.